Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:post-bronchodilator FEV1\<80% of predicted normal (ECSC) and a post-bronchodilator FEV1/FVC \<70% at Visit 1~2. Male or female patients, 40 years of age or older~3. Patients must be current or ex-smokers with a smoking history of more than 10 pack years:~Exclusion criteria:~1. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT \>x2 ULN, SGPT \>x2 ULN, bilirubin \>x2 ULN or creatinine \>x2 ULN~2. Patients with a history of asthma and/or total blood eosinophil count greater than 600/mm3~3. Patients with thyrotoxicosis, paroxysmal tachycardia (\>100 beats per minute)~4. Patients with a history of myocardial infarction within 1 year of screening visit, unstable or life-threatening cardiac arrhythmia, hospitalization for heart failure within the past year, known active tuberculosis, a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years, life-threatening pulmonary obstruction, cystic fibrosis, clinically evident bronchiectasis, significant alcohol or drug abuse~5. Patients who have undergone thoracotomy with pulmonary resection~6. Patients being treated with oral beta-adrenergics or oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.~7. Patients who regularly use daytime oxygen therapy for more than one hour per day.~8. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program~9. Pregnant or nursing women~10. Women of childbearing potential not using two effective methods of birth control (one barrier and one non-barrier).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olodaterol (BI 1744) Low (Type: EXPERIMENTAL): Low dose inhaled orally once daily from the Respimat inhaler
- Olodaterol (BI 1744) High (Type: EXPERIMENTAL): High dose inhaled orally once daily from the Respimat inhaler
- Formoterol 12mcg (Type: ACTIVE_COMPARATOR): 12mcg inhaled twice daily from the Aerolizer inhaler
- Placebo (Type: PLACEBO_COMPARATOR): Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).